在孟加拉国成年人中，与牛津-阿斯利康疫苗同源和异源剂量相关的副作用：一项观察性研究。
Side effects associated with homogenous and heterogenous doses of Oxford-AstraZeneca vaccine among adults in Bangladesh: an observational study.
机构信息
Department of Microbiology, Jahangirnagar University, Savar, Dhaka-1342, Savar, Dhaka, 1342, Bangladesh.
Department of Statistics and Data Science, Jahangirnagar University, Savar, Dhaka, 1342, Bangladesh.
出版信息
Sci Rep. 2024 Oct 11;14(1):23794. doi: 10.1038/s41598-024-75833-z.
Assessment of side effects associated with COVID-19 vaccination is required to monitor safety issues and acceptance of vaccines in the long term. We found a significant knowledge gap in the safety profile of COVID-19 vaccines in Bangladesh. We enrolled 1805 vaccine recipients from May 5, 2021, to April 4, 2023. Kruskal-Wallis test and χ2 test were performed. Multivariable logistic regression was also performed. First, second and third doses were administered among 1805, 1341, and 923 participants, respectively. Oxford-AstraZeneca (2946 doses) was the highest administered followed by Sinopharm BIBP (551 doses), Sinovac (214 doses), Pfizer-BioNTech (198 doses), and Moderna (160 doses), respectively. Pain at the injection site (80-90%, 3200-3600), swelling (85%, 3458), redness (78%, 3168), and heaviness in hand (65%, 2645) were the most common local effects, and fever (85%, 3458), headache (82%, 3336), myalgia (70%, 2848), chills (67%, 2726), muscle pain (60%, 2441) were the most prevalent systemic side effects reported within 48 h of vaccination. Thrombosis was only reported among the Oxford-AstraZeneca recipients (3.5-5.7%). Both local and systemic effects were significantly associated with the Oxford-AstraZeneca (p-value < 0.05), Pfizer-BioNTech (p-value < 0.05), and Moderna (p-value < 0.05) vaccination. Chronic urticaria and psoriasis were reported by 55-60% of the recipients after six months or later. The highest percentage of local and systemic effects after 2nd and 3rd dose were found among recipients of Moderna followed by Pfizer-BioNTech and Oxford-AstraZeneca. Homogenous doses of Oxford-AstraZeneca and heterogenous doses of Moderna and Pfizer-BioNTech were significantly associated with elevated adverse effects. Females, aged above 60 years with preexisting health conditions had higher risks. Vaccination with Pfizer-BioNTech (OR 4.34, 95% CI 3.95-4.58) had the highest odds of severe and long-term effects followed by Moderna (OR 4.15, 95% CI 3.92-4.69) and Oxford-AstraZeneca (OR 3.89, 95% CI 3.45-4.06), respectively. This study will provide an integrated insight into the safety profile of COVID-19 vaccines.
评估与 COVID-19 疫苗接种相关的副作用对于监测疫苗的安全性问题和长期接受程度至关重要。我们发现孟加拉国在 COVID-19 疫苗安全性方面存在显著的知识差距。我们于 2021 年 5 月 5 日至 2023 年 4 月 4 日期间招募了 1805 名疫苗接种者。进行了 Kruskal-Wallis 检验和 χ2 检验。还进行了多变量逻辑回归分析。1805 名参与者中分别接种了第一、第二和第三剂，1341 名和 923 名参与者中分别接种了牛津-阿斯利康（2946 剂）、国药集团 BIBP（551 剂）、科兴（214 剂）、辉瑞-BioNTech（198 剂）和 Moderna（160 剂）。最常见的局部不良反应是注射部位疼痛（80-90%，3200-3600）、肿胀（85%，3458）、发红（78%，3168）和手部沉重感（65%，2645），接种后 48 小时内最常见的全身不良反应是发热（85%，3458）、头痛（82%，3336）、肌痛（70%，2848）、寒战（67%，2726）和肌肉疼痛（60%，2441）。仅在牛津-阿斯利康接种者中报告了血栓形成（3.5-5.7%）。局部和全身不良反应均与牛津-阿斯利康（p 值 < 0.05）、辉瑞-BioNTech（p 值 < 0.05）和 Moderna（p 值 < 0.05）疫苗接种显著相关。60%至 65%的接种者在接种 6 个月或更长时间后报告慢性荨麻疹和银屑病。在 Moderna 之后，发现接受第二剂和第三剂 Moderna 和辉瑞-BioNTech 疫苗接种的人群中，局部和全身不良反应的比例最高。同源剂量的牛津-阿斯利康和异源剂量的 Moderna 和辉瑞-BioNTech 与不良反应升高显著相关。女性、年龄在 60 岁以上且有基础健康状况的人群风险更高。接种辉瑞-BioNTech（OR 4.34，95% CI 3.95-4.58）后出现严重和长期不良反应的几率最高，其次是接种 Moderna（OR 4.15，95% CI 3.92-4.69）和牛津-阿斯利康（OR 3.89，95% CI 3.45-4.06）。这项研究将为 COVID-19 疫苗的安全性概况提供综合见解。
Zotero 插件